6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
23m ago	TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss First Quarter 2026 Financial Results on May 8, 2026
24m ago	Aura Declares Dividend of US$0.78 Per Share and US$0.26 Per BDR Based on Q1 2026 Results, Resulting in a Dividend Yield of 4.5% in the LTM
49m ago	SmartCentres Real Estate Investment Trust Releases First Quarter Results for 2026
49m ago	Snow Peak Capital Announces Sale of Majority Interest in Dalco-GFT to Arvind Advanced Materials Limited
50m ago	DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference

About

Roivant Sciences Ltd. — investor relations, events, news, and company updates on 6ix.

Latest News

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

How Roivant Sciences Ltd. runs its investor program on 6ix — audience, formats, and program overview.

Recent Videos

Roivant Sciences Expansion of Brepocitinib & Phase 3 Study Results for Batoclimab in TED | April 02

Roivant Sciences Expansion of Brepocitinib & Phase 3 Study Results for Batoclimab in TED | April 02

Apr 03, 2026

Roivant Sciences: Analyst Love & Legal Wins! #StockMarket #InvestmentInsights #LegalWins

Roivant Sciences: Analyst Love & Legal Wins! #StockMarket #InvestmentInsights #LegalWins

Apr 01, 2026

Fri, Mar 20, 2026 🇯🇵 Roivant Sciences Insider Sold | ASIA Post-Market

Fri, Mar 20, 2026 🇯🇵 Roivant Sciences Insider Sold | ASIA Post-Market

Mar 21, 2026

Roivant Sciences Announces Genevant Sciences’ and Arbutus Biopharma’s $2 25 Billion Global Settlemen

Roivant Sciences Announces Genevant Sciences’ and Arbutus Biopharma’s $2 25 Billion Global Settlemen

Mar 04, 2026

Community Chat

Ask AI